CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Revenue from contract with customers	$ 142,672	$ 133,652
Cost of revenue:
Total cost of revenue	69,191	70,735
Gross profit	73,481	62,917
Selling, general and administrative expenses	41,318	32,164
Research and development	23,420	20,660
Amortization of intangible and acquisition-related assets	2,171	2,364
Income from operations	6,572	7,729
Interest expense	(2,136)	(3,143)
Other income, net	12	798
Equity in net (loss) income of unconsolidated investments	(398)	22
Loss (income) from continuing operations before income taxes	4,050	5,406
Income tax benefit (provision)	14,421	(1,106)
Income from continuing operations, net of tax	18,471	4,300
(Loss) income from discontinued operations	(5,021)	5,820
Gain on sale of discontinued operations	0	647
Income tax effect on discontinued operations	9,407	(1,710)
Income from discontinued operations, net of tax	4,386	4,757
Net income	$ 22,857	$ 9,057
Basic
Continuing operations	$ 0.16	$ 0.03
Discontinued operations	0.04	0.03
Net income per share - Basic	0.20	0.06
Diluted
Continuing operations	0.14	0.03
Discontinued operations	0.03	0.03
Net income per share - Diluted	$ 0.17	$ 0.06
Provider [Member]
Revenue:
Revenue from contract with customers	$ 118,665	$ 111,170
Cost of revenue:
Total cost of revenue	57,017	58,866
Payer & Life Sciences [Member]
Revenue:
Revenue from contract with customers	24,007	22,482
Cost of revenue:
Total cost of revenue	$ 12,174	$ 11,869